Experts in hematologic oncology give an overview of first- and second-line MDS treatment options, and discuss updates from the ASH 2022 Annual Meeting.
EP. 1: First- and Second-Line Treatment Options in Lower-Risk MDS
Hematologic oncology experts give an overview of first- and second-line treatment options for lower-risk myelodysplastic syndromes.
EP. 2: Luspatercept in Lower-Risk MDS
Following the ASH 2022 Annual Meeting, experts in hematologic oncology review updated data for luspatercept in lower-risk MDS.
EP. 3: Emerging Therapies for Lower-Risk MDS
Expert hematologic oncologists discuss updates from the ASH 2022 Annual Meeting on emerging therapies for lower-risk MDS.
Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC
Dr Nasioudis on the Use of NGS to Identify the Molecular Profile of Endometroid Ovarian Cancer
Dr Buckingham on the Use of Patient-reported Outcomes to Predict Frailty in Patients With Ovarian Cancer
Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma
2 Clarke Drive Cranbury, NJ 08512